首页> 外文期刊>Acta Haematologica >Primary thyroid marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type: Clinical manifestation and outcome of a rare disease - Consortium for improving survival of lymphoma study
【24h】

Primary thyroid marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type: Clinical manifestation and outcome of a rare disease - Consortium for improving survival of lymphoma study

机译:黏膜相关淋巴样组织类型的原发性甲状腺边缘区B细胞淋巴瘤:一种罕见疾病的临床表现和预后-提高淋巴瘤生存率的研究机构

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: Primary thyroid marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type (pTY-MZL) is an extremely uncommon form of lymphoma. Due to its rarity, the natural history and optimal treatment modality for this disease have yet to be clearly established. Methods: A total of 27 patients with histologically confirmed pTY-MZL were retrospectively analyzed. Results: The median age of our subjects was 53 years (range 25-82). This study involved 17 females (63.0%) and 10 males (37.0%). Twenty-four out of 27 patients (88.9%) initially presented with localized disease, defined by Ann Arbor stage I/II. Bone marrow involvement was detected in 8.3% of the patients (2 patients), and 91.7% of the patients (25 of 27) were categorized into the low or low-intermediate risk group, according to the International Prognostic Index criteria. Accompanying Hashimoto's thyroiditis was detected in 72% of the patients, whereas thyroglobulin antibody levels were elevated in 70% of the patients. Twenty-six patients were treated with surgery, radiotherapy or chemotherapy, and 25 patients achieved complete remission. During the follow-up period, only 2 patients evidenced progression, and no deaths occurred over the course of the study. Conclusion: pTY-MZL tends to be an indolent disease. However, unlike other mucosa-associated lymphoid tissue site MZLs, pTY-MZL was well controlled via several treatment modalities, and the patients' responses were sustained for a prolonged period.
机译:目的:黏膜相关淋巴样组织类型的原发性甲状腺边缘区B细胞淋巴瘤(pTY-MZL)是一种极为罕见的淋巴瘤。由于其稀有性,该病的自然病史和最佳治疗方式尚未明确。方法:回顾性分析27例经组织学证实为pTY-MZL的患者。结果:我们受试者的中位年龄为53岁(范围为25-82)。这项研究涉及17位女性(63.0%)和10位男性(37.0%)。 27例患者中有24例(88.9%)最初表现为局部疾病,由Ann Arbor I / II期定义。根据国际预后指数标准,在8.3%的患者(2例患者)中检测到了骨髓受累,并且91.7%的患者(27例中的25例)被分为低风险或低中度风险组。在72%的患者中发现了伴随桥本甲状腺炎的情况,而在70%的患者中甲状腺球蛋白抗体水平升高。 26例患者接受了手术,放疗或化学疗法治疗,其中25例完全缓解。在随访期间,只有2名患者表现出进展,并且在研究过程中未发生死亡。结论:pTY-MZL是一种惰性疾病。但是,与其他与粘膜相关的淋巴样组织部位MZL不同,pTY-MZL通过多种治疗方式得到了很好的控制,患者的反应持续了很长时间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号